Interactions between Fluconazole and Saccharomyces boulardii lyo

Fluconazole has a moderate potential interaction with Arrhythmia.

Some azole antifungals have been associated with prolongation of the QT interval on the ECG. Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications. These drugs should be administered with caution to patients with potentially proarrhythmic conditions, such as congenital/acquired QT prolongation, cardiomyopathy (especially when heart failure is present), sinus bradycardia, and existing symptomatic arrhythmias. Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.

Saccharomyces boulardii lyo has a major potential interaction with Bone Marrow Depression/Low Blood Counts.

Saccharomyces boulardii lyo probiotics should not be used in pre- or post- organ or bone marrow transplant patients and other patients considered severely immunocompromised or critically ill.

Saccharomyces boulardii lyo has a major potential interaction with Bone Marrow Transplantation.

Saccharomyces boulardii lyo probiotics should not be used in pre- or post- organ or bone marrow transplant patients and other patients considered severely immunocompromised or critically ill.

Fluconazole has a moderate potential interaction with Hemodialysis.

Fluconazole is substantially removed by hemodialysis. Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis. Fluconazole should be administered after hemodialysis.

Saccharomyces boulardii lyo has a major potential interaction with Immunodeficiency.

Saccharomyces boulardii lyo probiotics should not be used in pre- or post- organ or bone marrow transplant patients and other patients considered severely immunocompromised or critically ill.

Saccharomyces boulardii lyo has a moderate potential interaction with Immunodeficiency.

Probiotics, especially those containing lactobacillus, should be used with caution in immunosuppressed patients.

Fluconazole has a major potential interaction with Liver Disease.

The use of fluconazole has been rarely associated with hepatotoxicity. Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications. Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy. Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.

Saccharomyces boulardii lyo has a major potential interaction with Organ Transplant.

Saccharomyces boulardii lyo probiotics should not be used in pre- or post- organ or bone marrow transplant patients and other patients considered severely immunocompromised or critically ill.

Fluconazole has a moderate potential interaction with Renal Dysfunction.

Fluconazole is primarily eliminated by the kidney. Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance. Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.